BioSpace News Archive

Arrowhead Pharmaceuticals Inc. presented additional positive interim 48-week liver biopsy results from the ongoing AROAAT2002 study at The International Liver Congress - The Annual Meeting of the European Association for the Study of the Liver.

Camurus announced that the New Drug Application by Camurus’ US licensee Braeburn for Brixadi™ extended-release weekly and monthly injection for subcutaneous use for moderate to severe opioid use disorder was accepted for review by the US Food and Drug Administration.

Italfarmaco Group announced topline data from its proof-of-concept Phase 2 trial with Givinostat, the company’s proprietary histone deacetylase inhibitor, in 51 adult males with Becker Muscular Dystrophy.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced promising results from its latest pivotal trial for the Omnipod 5 Automated Insulin Delivery System in very young children.

Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses in adults with type 2 diabetes after 40 weeks of treatment in Eli Lilly and Company’s SURPASS-1 monotherapy clinical trial evaluating the efficacy and safety of tirzepatide compared to placebo.

Novo Nordisk presented data showing that an investigational 2 mg dose of Ozempic® injection provided statistically significant and superior reductions in blood sugar compared with Ozempic® 1 mg.

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus infection, as well as therapies to treat coronaviruses, announced the presentation of five abstracts at the European Association for the Study of the Liver International Liver CongressTM.

Sanyou Biopharmaceutical Co., Ltd., a leading company in innovative antibody drug discovery, announced the closing of series B financing.

Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. announced positive interim data from an ongoing Phase 1 clinical study of their lead in vivo genome editing candidate, NTLA-2001, which is being developed as a single-dose treatment for transthyretin amyloidosis.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.